Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1969 1
1972 2
1974 1
1977 1
1980 2
1981 1
1982 3
1983 6
1984 1
1985 1
1986 2
1987 1
1988 2
1992 1
1993 2
1994 3
1995 1
1997 2
2000 2
2001 2
2002 1
2003 2
2004 2
2005 4
2006 4
2007 8
2008 7
2009 3
2010 7
2011 6
2012 4
2013 4
2014 13
2015 10
2016 13
2017 6
2018 10
2019 4
2020 11
2021 9
2022 4
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
LLT1-CD161 Interaction in Cancer: Promises and Challenges.
Braud VM, Meghraoui-Kheddar A, Elaldi R, Petti L, Germain C, Anjuère F. Braud VM, et al. Among authors: germain c. Front Immunol. 2022 Feb 4;13:847576. doi: 10.3389/fimmu.2022.847576. eCollection 2022. Front Immunol. 2022. PMID: 35185935 Free PMC article. Review.
Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer.
Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S, Bizouard G, Validire P, Damotte D, Alifano M, Magdeleinat P, Cremer I, Teillaud JL, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Germain C, et al. Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44. doi: 10.1164/rccm.201309-1611OC. Am J Respir Crit Care Med. 2014. PMID: 24484236
Trial of Lixisenatide in Early Parkinson's Disease.
Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O; LIXIPARK Study Group. Meissner WG, et al. Among authors: germain c. N Engl J Med. 2024 Apr 4;390(13):1176-1185. doi: 10.1056/NEJMoa2312323. N Engl J Med. 2024. PMID: 38598572 Clinical Trial.
Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys.
Mateo M, Reynard S, Pietrosemoli N, Perthame E, Journeaux A, Noy K, Germain C, Carnec X, Picard C, Borges-Cardoso V, Hortion J, Lopez-Maestre H, Regnard P, Fellmann L, Vallve A, Barron S, Jourjon O, Lacroix O, Duthey A, Dirheimer M, Daniau M, Legras-Lachuer C, Carbonnelle C, Raoul H, Tangy F, Baize S. Mateo M, et al. Among authors: germain c. Nat Commun. 2023 Mar 11;14(1):1352. doi: 10.1038/s41467-023-37050-6. Nat Commun. 2023. PMID: 36906645 Free PMC article.
Regulatory T cells infiltrate the tumor-induced tertiary lymphoïd structures and are associated with poor clinical outcome in NSCLC.
Devi-Marulkar P, Fastenackels S, Karapentiantz P, Goc J, Germain C, Kaplon H, Knockaert S, Olive D, Panouillot M, Validire P, Damotte D, Alifano M, Murris J, Katsahian S, Lawand M, Dieu-Nosjean MC. Devi-Marulkar P, et al. Among authors: germain c. Commun Biol. 2022 Dec 24;5(1):1416. doi: 10.1038/s42003-022-04356-y. Commun Biol. 2022. PMID: 36566320 Free PMC article.
Shaping of an effective immune microenvironment to and by cancer cells.
Becht E, Goc J, Germain C, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH. Becht E, et al. Among authors: germain c. Cancer Immunol Immunother. 2014 Oct;63(10):991-7. doi: 10.1007/s00262-014-1590-3. Epub 2014 Aug 12. Cancer Immunol Immunother. 2014. PMID: 25112529 Review.
Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial.
Tschismarov R, Van Damme P, Germain C, De Coster I, Mateo M, Reynard S, Journeaux A, Tomberger Y, Withanage K, Haslwanter D, Terler K, Schrauf S, Müllner M, Tauber E, Ramsauer K, Baize S. Tschismarov R, et al. Among authors: germain c. Lancet. 2023 Apr 15;401(10384):1267-1276. doi: 10.1016/S0140-6736(23)00048-X. Epub 2023 Mar 16. Lancet. 2023. PMID: 36934733 Free article. Clinical Trial.
163 results